DZ Bank’s Protagonist Therapeutics PTGX Stock Holding History

DZ Bank’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-13,100	Closed	-$113K	–	1034
2018 Q1	$113K	Buy	+13,100	New	+$247K	﹤0.01%	991

Other funds holding PTGX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

DZ Bank's PTGX Position: Q2 2018 in Review

DZ Bank sold out of Protagonist Therapeutics (PTGX) in Q2 2018, closing a stake of 13,100 shares — an estimated $113K sold.

DZ Bank first reported a position in PTGX in Q1 2018 and held it in 1 quarter. The position peaked at $113K in Q1 2018. 69 funds tracked by Wall St. Rank hold PTGX as of Q2 2018.

DZ Bank reported no remaining Protagonist Therapeutics position as of Q2 2018 after selling out during the quarter.
DZ Bank sold 13,100 Protagonist Therapeutics shares in Q2 2018, an estimated $113K.
DZ Bank first reported a position in Protagonist Therapeutics in Q1 2018 and held it in 1 quarter.
DZ Bank's Protagonist Therapeutics position peaked at $113K in Q1 2018.
69 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2018.

Based on DZ Bank's 13F filing for Q2 2018, filed 14 Aug 2018.